IGC Pharma, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IGC Pharma, Inc. (IGC) operates as a clinical-stage pharmaceutical company that develops treatments for Alzheimer’s disease and related dementias, with operations in the United States, Colombia, India, and Canada; the firm, founded in 2005 and headquartered in Potomac, Maryland, maintains a vertically integrated model encompassing research and development, clinical trials, and manufacturing capabilities at facilities in Potomac, Maryland, and Vancouver, Washington. Its lead product candidate, IGC-AD1, a partial CB1 receptor agonist with anti-inflammatory properties, advances through the multicenter Phase 2 CALMA clinical trial evaluating safety and efficacy for agitation in dementia due to Alzheimer’s disease, having surpassed 50% patient enrollment as of recent updates; the preclinical pipeline features TGR-63, a small molecule inhibitor of amyloid plaque aggregation that crosses the blood-brain barrier and demonstrates behavioral efficacy in Alzheimer’s mouse models, alongside IGC-M3 and LMP targeting Alzheimer’s pathology, IGC-1C addressing metabolic disorders and Alzheimer’s, and IGC-1A for metabolic conditions; the company also offers Holiby, a wellness brand with science-backed over-the-counter formulations for cellular health, energy metabolism, cognitive function, immunity, and women’s health needs like premenstrual syndrome relief, manufactured at its Washington state facility, alongside Holief for menstrual cramps. IGC Pharma recently launched Holiby in 2025 to tap the $75 billion wellness market for near-term revenue while progressing pharmaceutical assets, accelerated CALMA trial enrollment and reported positive TGR-63 preclinical results in June 2024, secured National Institute on Aging recognition for its AI-powered MINT-AD platform aiding early Alzheimer’s detection via multimodal data analysis with planned academic and clinical pilots, extended a $12 million loan agreement with O-Bank Co. Ltd. through July 2025, formed a strategic partnership with a leading biotechnology firm in 2025 to enhance research and pipeline expansion, and rebranded from India Globalization Capital, Inc. in March 2023 to reflect its sharpened focus on Alzheimer’s therapeutics.
Company News
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Short Interest Up 15.9% in February